[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354976-105":59,"doc-detail-354976-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comorbidities-medication-use-and-overall-survival-in-eight-cancers-a-multinational-cohort-study-of-17-million-patients-across-europe","Comorbidities, medication use, and overall survival in eight cancers - a multinational cohort study of 1.7 million patients across Europe","","Real-world evidence is used to examine cancer burden, clinical presentation, and differences in care across regions. A large federated study analyzes patient characteristics and overall survival for eight cancer types using data from 11 electronic health records and cancer registries in eight European countries, standardized to the OMOP-CDM. Adults diagnosed between 2000 and 2019 are followed from diagnosis to death or study end.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comorbidities-medication-use-and-overall-survival-in-eight-cancers-a-multinational-cohort-study-of-17-million-patients-across-europe/354976/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comorbidities-medication-use-and-overall-survival-in-eight-cancers-a-multinational-cohort-study-of-17-million-patients-across-europe/354976.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data sources and standardization were used in the study?","Question",{"text":112,"@type":113},"The study uses 11 electronic health records and cancer registries from eight European countries, mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and how long were they followed?",{"text":117,"@type":113},"Patients aged 18+ with primary cancer diagnoses between 2000 and 2019 were included. Follow-up ran from cancer diagnosis until death, database exit, or the study end.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were evaluated regarding survival?",{"text":121,"@type":113},"Age-standardised overall survival was calculated at one, five, and ten years using the Kaplan–Meier method and stratified by cancer type, age group, and sex.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354976,1790450710,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Articles  \nComorbidities, medication use, and overall survival in eight cancers: a multinational cohort study of 1.7 million patients across Europe  \nIrene López-Sánchez,a,b Anna Palomar-Cros,a Ravinder Claire,c Laura Pérez-Crespo,a Agustina Giuliodori,a Ian Koblbauer,d Jeremy Dietz,c Jamie Elvidge,c James Koh,c Asieh Golozar,e Juan Manuel Ramirez-Anguita,f Angela Leis,f Miguel-Angel Mayer,f,g Nicola Symmers,h Mahéva Vallet,h Colin McLean,h Peter S. Hall,h Mees Mosseveld,i Katia Verhamme,i Espen Enerly,j Peter Prinsen,k Jelle Evers,k Marek Oja,l Raivo Kolde,l Rafael Marcos-Gragera,m,n Eric Fey,o,p Kimmo Porkka,o,p Tiago Taveira-Gomes,q,r,s Fernanda Estevinho,t Alberto Moreno Conde,u,v Jesus Moreno Conde,u,v Carlos Miguez Sanchez,v Evelyne Fournier,w Andrea Pistillo,a Xihang Chen,d George Corby,d Abigail Robinson,d Maria T. Sanchez-Santos,d Antonella Delmestri,d Wai Yi Man,d Martí Català,d Marta Alcalde-Herraiz,d Edward Burn,d Daniel Prieto-Alhambra,d,i Talita Duarte-Salles,a,i,∗ and Danielle Newbyd  \naFundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain bPrograma de Doctorat en Metodologia de la Recerca Biomèdica i Salut Pública, Universitat Autònoma de Barcelona, Barcelona, Cerdanyola del Vallès, Spain  \ncNational Institute for Health and Care Excellence, London, United Kingdom  \ndCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, United Kingdom  \neNemesis Health, New York, USA  \nfResearch Programme on Biomedical Informatics, Hospital del Mar Research Institute, Doctor Aiguader 88, 08003, Barcelona, Spain gData Science Unit, Hospital del Mar, Passeig Maritim 25-29, 08003, Barcelona, Spain  \nhEdinburgh Cancer Research Centre, Institute of Genetics and Cancer, The University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, United Kingdom  \niErasmus MC University Medical Center, Rotterdam, the Netherlands  \njDepartment of Research, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway kNetherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands  \nlInstitute of Computer Science, University of Tartu, Narva mnt 18, 51009, Tartu, Estonia  \nmEpidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology (ICO), CIBER of Epidemiology and Public Health (CIBERESP), Girona, Spain  \nnBiomedical Research Institute (IDIBGI-CERCA), Josep Carreras Leukemia Research Institute, Department of Medical Sciences, Medical School, University of Girona, Girona, Spain  \noHUS Helsinki University Hospital, Helsinki, Finland  \npiCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland  \nqDepartment of Community Medicine, Information and Decision in Health, Faculty of Medicine, University of Porto, Porto, Portugal rFaculty of Health Sciences, University Fernando Pessoa, Porto, Portugal  \nsSIGIL Scientific Enterprises, Dubai, United Arab Emirates  \ntDepartment of Oncology, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal  \nuInstitute of Biomedicine of Seville, IBiS/Virgen Macarena University Hospital/CSIC/University of Seville, Seville, Spain vHospital Universitario Virgen Macarena, Seville, Spain  \nwUniversité de Genève, Geneva, Switzerland  \nSummary  \nBackground Real-world evidence provides valuable insights into cancer burden, presentation, and care variations. Through a large-scale federated approach, this study aims to explore patient characteristics and overall survival for eight cancers using data from 11 electronic health records and cancer registries from eight European countries, mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) .  \nMethods Patients aged 18 years or older with a primary cancer diagnosis between 2000 and 2019 were included. Patients were followed from cancer diagnosis un","cbCaiiG2wNMrlcxO","https://ap.wps.com/l/cbCaiiG2wNMrlcxO","pdf",1613955,15,"English","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation","[{\"question\":\"What data sources and standardization were used in the study?\",\"answer\":\"The study uses 11 electronic health records and cancer registries from eight European countries, mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM).\"},{\"question\":\"How were patients selected and how long were they followed?\",\"answer\":\"Patients aged 18+ with primary cancer diagnoses between 2000 and 2019 were included. Follow-up ran from cancer diagnosis until death, database exit, or the study end.\"},{\"question\":\"What outcomes were evaluated regarding survival?\",\"answer\":\"Age-standardised overall survival was calculated at one, five, and ten years using the Kaplan–Meier method and stratified by cancer type, age group, and sex.\"}]","Comorbidities, medication use, and overall survival in eight cancers - a multinational cohort study of 1.7 million patients across Europe | PDF",1790115200,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8697ef6392de334d96bbd66ab53cd864.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73026870ba0e613389153e0284472654.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab428d585089ebeb061e74ef84ac5339.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/687ac4a51691fb620d8e2377e18db964.webp",980,1306]